Zito Julie M, Tobi Hilde, de Jong-van den Berg Lolkje T W, Fegert Joerg M, Safer Daniel J, Janhsen Katrin, Hansen Dorte Gilså, Gardner James F, Glaeske Gerd
University of Maryland, Baltimore, MD 21201, USA.
Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):793-8. doi: 10.1002/pds.1254.
To compare antidepressant prevalence data in youths across three western European countries (Denmark, Germany, and the Netherlands) with US regional data in terms of age and gender and to show proportional subclass antidepressant (ATD) use.
A population-based analysis of administrative claims data for the year 2000 was undertaken in 0 to 19-year-old enrollees who were part of the insured populations from four countries having a total of from 72,570 to 480,680 members.
ATD medication utilization in the US dataset (1.63%) exceeded that of three Western European countries (prevalence ranged from 0.11 to 0.54%) by at least 3-fold. There were major variations in the use of subclasses: tricyclic antidepressants (TCAs) predominated in Germany while selective serotonin reuptake inhibitors (SSRIs) predominated in the US, Denmark and the Netherlands.
Cross-national variations should be further explored to understand the factors related to these differences and how prevalence differences relate to effectiveness and safety. Community-based cohorts should be followed to establish outcomes in the usual practice setting.
比较三个西欧国家（丹麦、德国和荷兰）青少年的抗抑郁药使用流行率数据与美国地区在年龄和性别方面的数据，并展示抗抑郁药各亚类的使用比例。
对2000年的行政索赔数据进行基于人群的分析，研究对象为来自四个国家参保人群中0至19岁的登记人员，这四个国家的参保人数总计从72,570至480,680人不等。
美国数据集中抗抑郁药的使用比例（1.63%）比三个西欧国家（流行率在0.11%至0.54%之间）至少高出3倍。各亚类药物的使用存在重大差异：德国以三环类抗抑郁药（TCA）为主，而美国、丹麦和荷兰则以选择性5-羟色胺再摄取抑制剂（SSRI）为主。
应进一步探究跨国差异，以了解导致这些差异的因素，以及流行率差异与有效性和安全性之间的关系。应追踪基于社区的队列，以确定常规实践环境中的结果。
